Reply to“Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease:Potential therapeutic implications”

摘要

The Author Reply:We sincerely appreciated the interest of Polyzos et al.,in our review article and sharing their improvised thoughts regard-ing the Wnt signaling modulators for the treatment of post-menopausal women with osteoporosis and nonalcoholic fatty liver disease(NAFLD).Several experimental studies have showed that the aberrant Wnt/β-catenin signaling promotes the development and/or progression of a variety of chronic liver diseases including NAFLD[1,2].Therefore,our review emphasized on the modulation of Wnt/β-catenin signaling and the role of its mediators in NAFLD progression.Given that NAFLD prevalence is constantly increas-ing,and that osteoporosis is associated with women over 50 years of age with NAFLD[3],there is an unmet need for an effective treatment.Sclerostin blocks the canonical Wnt signaling pathway of bone formation.Therefore,romosozumab,a humanized anti-sclerostin monoclonal antibody,was approved for the treatment of osteoporosis.Romosozumab binds to sclerostin,permitting the en-gagement of Wnt ligands with their co-receptors,resulting in an increase in bone formation and bone mineral density.